{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-skin-infection-scalp/management/management/","result":{"pageContext":{"chapter":{"id":"263ea5e0-37c2-539f-8fd6-e1218c2c16a1","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 1f56bc1a-e7bb-4ee7-bfee-08b1caf87790 --><h2>Scenario: Management of fungal skin infection - scalp</h2><!-- end field 1f56bc1a-e7bb-4ee7-bfee-08b1caf87790 -->","summary":"Covers the management of people with suspected fungal scalp infection, and the management of contacts.","htmlStringContent":"<!-- begin item 95ce7c98-035f-45c9-a9b7-d654b97a39aa --><!-- begin field af6c089b-c47f-45a6-ac13-acbd00872079 --><p>From age 1 month onwards.</p><!-- end field af6c089b-c47f-45a6-ac13-acbd00872079 --><!-- end item 95ce7c98-035f-45c9-a9b7-d654b97a39aa -->","topic":{"id":"2366ecbc-4749-5ca6-8bc3-3873089df3da","topicId":"0fd8e2d0-69ae-41e6-b283-543453f673bc","topicName":"Fungal skin infection - scalp","slug":"fungal-skin-infection-scalp","lastRevised":"Last revised in April 2018","chapters":[{"id":"8a51d4c9-69eb-58f9-ac0b-38f666f1f848","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"97441633-de03-58fd-9e1b-bb42c2828337","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7bc5a70d-2277-5bff-9951-bb0c0ab337ef","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f9145ac8-339e-59bb-b8ad-25b709acdacb","slug":"changes","fullItemName":"Changes"},{"id":"d0c182d2-7ce4-57e0-9dee-362b0b530365","slug":"update","fullItemName":"Update"}]},{"id":"6f048cdd-1cbb-5611-a5e0-8361b221db8a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"599dbe6a-d7a3-5f91-91ed-4be709b1180c","slug":"goals","fullItemName":"Goals"},{"id":"84c3bfe1-6c40-57e4-a749-77a9946a89e3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ac49d0bf-50dc-5071-a82b-62723de01de5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"60065f70-8af3-5f60-9dca-ff069607e2bc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fba31ad2-44ba-5fe6-bf46-7345ab044a0e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d12ccb71-eddd-5517-8749-1217ba0b4eb6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba0c5ffb-2309-5d72-90e0-4c09ec2762ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a7a6e00a-8e02-5305-be1d-1aa4389187a5","slug":"definition","fullItemName":"Definition"},{"id":"a7f24440-b63f-56f4-8c94-3bb4b1877412","slug":"prevalence","fullItemName":"Prevalence"},{"id":"015c5679-e685-58cd-b557-2ed3559a9603","slug":"complications","fullItemName":"Complications"},{"id":"8fa3f79d-ba1c-5733-8306-100d8afeabfb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"fa2925a0-ec3e-5255-b9f9-7959141a2e82","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b464e67b-56da-51d3-a0d4-4577dd9c24f7","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"4d8408bc-15aa-5151-a55a-b7849dcb8387","slug":"assessment","fullItemName":"Assessment"},{"id":"67ef57a0-32a1-5271-8ef9-7a7e9e1e5a24","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"05c0fb7d-20c2-5b68-9935-1d3c3f46f68d","fullItemName":"Management","slug":"management","subChapters":[{"id":"263ea5e0-37c2-539f-8fd6-e1218c2c16a1","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2c583161-dd9d-5bf1-9fb1-a1395842cac9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b923eed5-33a1-596e-974f-5611050a47c7","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"eb8ea077-2ef7-5dd1-b454-43ca5a07d5a0","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"},{"id":"599d0b59-095a-52c5-8bd1-289c5e9c48af","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"e6d4f0f1-7501-5b3f-9954-957d8152ffb7","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"cc03af24-7789-56ce-978f-b905a9611cb5","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ce8e8c93-7919-5160-9ad5-965fcd16658f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e05609c9-c42a-5eec-b055-39a296c3e2ea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e4f27b22-bcda-54f2-83f3-4ebf35f962ba","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0ce2862f-cdca-57b0-9998-9bc40799914a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7e057656-6867-5510-95c7-019671326f4b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"687c951d-457b-52b6-93f8-e38d5eafe6ed","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f17589e6-56a0-535c-aa03-0856855943bb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"05c0fb7d-20c2-5b68-9935-1d3c3f46f68d","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"c9026cfe-216b-5722-a2ef-a731271054b4","slug":"management-of-index-cases","fullItemName":"Management of index cases","depth":3,"htmlHeader":"<!-- begin field b7dae5bc-dd8b-4b13-8b7a-4b99549ae336 --><h3>How should I manage a person with fungal scalp infection?</h3><!-- end field b7dae5bc-dd8b-4b13-8b7a-4b99549ae336 -->","summary":null,"htmlStringContent":"<!-- begin item 6227a783-1c5c-4694-89a6-d8d5da29e56e --><!-- begin field 94bc4018-7ee9-4208-8ced-0ebeeac115e3 --><p><strong>The management of fungal scalp infection depends on the site and severity of scalp and hair involvement, the causative organism, the person's symptoms, and any co-morbidities.</strong></p><ul><li><strong>If the person has a suspected <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/diagnosis/diagnosis/\">kerion</a>, arrange urgent <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/management/management/#follow-up-referral\">referral</a> to a dermatology specialist.</strong></li><li><strong>Advise on self-care management strategies:</strong><ul><li>Soften any surface crusts (for example, by applying moistened dressings to affected areas), and then gently tease away.</li><li>Discard or disinfect objects that can transmit fungal spores, such as hats, scarves, hairbrushes, combs, pillows, blankets, and scissors, to prevent re-infection or transmission of infection to others.</li><li>Do not share towels, and ensure they are washed frequently.</li><li>Parents or carers should inspect the scalps of other children and household contacts regularly for <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/diagnosis/diagnosis/\">clinical signs</a> of infection, and <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/management/management/#management-of-contacts\">manage</a> appropriately.</li><li>If a household pet is suspected of being the source of infection, it should be assessed and treated by a vet.</li></ul></li><li><strong>Provide information on sources of advice and support, such as:</strong><ul><li>The British Association of Dermatologists information leaflet <a data-hyperlink-id=\"3d46fa23-285e-46a9-8a03-a98c00fd91ea\" href=\"http://www.bad.org.uk/shared/get-file.ashx?id=1965&itemtype=document\" target=\"_blank\">Tinea capitis (or scalp ringworm)</a>.</li><li>The NHS information on <a data-hyperlink-id=\"45e06781-5b0d-46e6-b7d1-a98c00fd91fd\" href=\"https://www.nhs.uk/conditions/ringworm/\" target=\"_blank\">Ringworm</a>.</li></ul></li><li><strong>In adults, offer treatment with an oral antifungal agent if there is:</strong><ul><li>A positive skin and hair sample microscopy <em>or</em> culture result.</li><li>A negative mycology result, but clinical features are very suggestive of infection.<ul><li>Arrange for repeat <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/diagnosis/assessment/#skin-hair-sampling\">skin and hair sampling</a>, and start oral antifungal treatment.</li></ul></li><li>A strong clinical suspicion of fungal scalp infection before mycology results are back, depending on clinical judgement.</li></ul></li><li><strong>In children, consider offering treatment with an oral antifungal agent in primary care:</strong><ul><li>Prescribe an oral antifungal agent if the diagnosis is certain <em>and</em> there is appropriate experience and expertise in prescribing treatment in primary care, <em>or</em></li><li>Seek specialist advice from a paediatric dermatologist before starting treatment.</li><li>Advise that once appropriate treatment is started, they should attend school or nursery as normal.</li></ul></li><li><strong>If oral antifungal treatment is offered in primary care:</strong><ul><li>Prescribe either oral griseofulvin (licensed) or oral terbinafine (off-label) empirically until culture results are available.<ul><li>If the person lives in an urban area, start treatment with terbinafine for 4 weeks.</li><li>If the person lives in a rural area, start treatment with griseofulvin for 4–8 weeks.</li><li>See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/prescribing-information/oral-terbinafine/\">Oral terbinafine</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/prescribing-information/oral-griseofulvin/\">Oral griseofulvin</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/prescribing-information/\">Prescribing information</a> for more detailed information on drug doses, contraindications and cautions, adverse effects, and drug interactions.</li></ul></li><li>When the culture results are available:<ul><li>If the infective organism is <em>Trichophyton tonsurans</em>, continue terbinafine (if taking already), or switch to treatment with terbinafine.</li><li>If the infective organism is a <em>Microsporum </em>species, continue griseofulvin (if taking already), or switch to treatment with griseofulvin.</li><li>Consider the use of itraconazole (off-label indication) for 4 weeks if griseofulvin is not tolerated or is contraindicated. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/prescribing-information/oral-itraconazole/\">Oral itraconazole</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/prescribing-information/\">Prescribing information</a> for more detailed information on drug doses, contraindications and cautions, adverse effects, and drug interactions.</li></ul></li></ul></li><li><strong>Consider c</strong><strong>o-prescribing a topical antifungal agent during initial oral antifungal treatment,</strong> to reduce the risk of transmission to other people.<ul><li>Options include selenium sulfide or ketoconazole shampoo to be used at least twice weekly for 2–4 weeks, or an imidazole cream (in children less than 5 years of age) to be used daily for one week.<ul><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/prescribing-information/topical-antifungals/\">Topical antifungals</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/prescribing-information/\">Prescribing information</a> for more information on different preparations which are licensed for different age-groups.</li></ul></li></ul></li><li><strong>Assess and manage any possible <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/background-information/complications/\">complications</a>:</strong><ul><li>If there is suspected secondary infection, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cellulitis-acute/\">Cellulitis - acute</a> and <a class=\"topic-reference external-reference\" href=\"/topics/impetigo/\">Impetigo</a> for more information.<ul><li>Be aware that pustule formation may represent an inflammatory response to the dermatophyte itself rather than a secondary bacterial infection.</li></ul></li><li>If there is a suspected id reaction, advise the person to continue oral antifungal treatment as prescribed.<ul><li>Consider prescribing a topical corticosteroid for symptom relief, if needed. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for more information.</li></ul></li></ul></li><li><strong>Review the person 4–8 weeks after completing the course of oral antifungal treatment to assess the response to treatment:</strong><ul><li>Assess for signs of normal hair regrowth suggesting clearance of infection, or for signs of <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/management/management/#follow-up-referral\">treatment failure</a>.</li></ul></li></ul><!-- end field 94bc4018-7ee9-4208-8ced-0ebeeac115e3 --><!-- end item 6227a783-1c5c-4694-89a6-d8d5da29e56e -->","subChapters":[{"id":"e81eedd6-5388-5878-992c-af9b89279524","slug":"basis-for-recommendation-935","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field ad1658a3-f7f5-4546-b992-dce8b1f23bfd --><h4>Basis for recommendation</h4><!-- end field ad1658a3-f7f5-4546-b992-dce8b1f23bfd -->","summary":null,"htmlStringContent":"<!-- begin item 935004a8-bd0e-4f9e-a0a8-fea5781911bb --><!-- begin field 301835f2-411e-4a2d-8669-f0bd2f9d50b2 --><p>The recommendations on the management of index cases are largely based on expert opinion in the British Association of Dermatologists' (BAD) <em>Guidelines for the management of tinea capitis 2014</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>], the European Society for Pediatric Dermatology (ESPD) practice guidelines <em>Guidelines for the management of tinea capitis in children</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Kakourou et al, 2010</a>], the Public Health England (PHE) publications <em>Fungal skin and nail infections: Diagnosis and laboratory investigation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">PHE, 2017</a>] and <em>Health protection in schools and other childcare facilities</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">PHE, 2018</a>], a Cochrane systematic review <em>Systemic antifungal therapy for tinea capitis in children</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Chen, 2016</a>], two meta-analyses comparing griseofulvin and terbinafine treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Tey et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Gupta and Drummond-Main, 2013</a>], and expert opinion in review articles on fungal scalp infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Hay, 2017</a>] and in review articles on fungal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Ely, 2014</a>].</p><h5>Advice on self-care strategies</h5><ul><li>The recommendations on self-management are largely based on the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Hay, 2017</a>].<ul><li>Removal of surface crusts may relieve itching and discomfort, and may help to reveal and manage any underlying secondary bacterial infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Hay, 2017</a>].</li><li>If a person has a confirmed zoophilic infection such as <em>Microsporum canis</em>, it is important to identify and treat the animal source of infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Hay, 2017</a>].</li></ul></li></ul><h5>Management of children</h5><ul><li>The recommendation on considering treating children with oral antifungal therapy in primary care is extrapolated from expert opinion in the BAD guidelines, as griseofulvin is the only drug licensed for the treatment of fungal scalp infection in children in the UK, however, it notes that off-label prescribing is well established [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>]. This recommendation is also pragmatic, based on the expert opinion of previous external reviewers of this CKS topic.</li><li>The recommendation on attending school or nursery is based on the PHE document on health protection in schools and other childcare facilities, which states that exclusion is not needed once appropriate antifungal treatment has been started [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">PHE, 2018</a>].</li></ul><h5>Prescribing oral antifungal treatment</h5><ul><li>The recommendation to offer oral antifungal treatment to adults before culture results are available if there is a strong clinical suspicion of infection is based on expert opinion in the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">PHE, 2017</a>], and is also extrapolated from the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Ely, 2014</a>].<ul><li>In high-risk populations, a delay in starting treatment may increase the risk of spread of infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>]. Treatment for clinically obvious or severe cases should not be delayed until culture results are available [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Moriarty et al, 2012</a>].</li></ul></li><li>The recommendation to use oral antifungal treatment (and not topical antifungal monotherapy) for fungal scalp infection is based on expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>], the ESPD practice guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Kakourou et al, 2010</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Ely, 2014</a>].<ul><li>Oral antifungal treatments can penetrate and eradicate hair shaft infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Kakourou et al, 2010</a>], whereas topical antifungal agents do not penetrate down to the deepest part of the hair follicle [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>].</li><li>The BAD guidelines highlight that the optimal treatment regimen varies according to the causative dermatophyte organism, which will vary geographically.</li></ul></li></ul><h5>Prescribing oral terbinafine treatment</h5><ul><li>The recommendation to consider prescribing terbinafine first-line for <em>Trichophyton</em> infections is based on the fact it is has high fungicidal activity against this dermatophyte compared with <em>Microsporum</em> species [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Tey et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>], has similar efficacy to griseofulvin treatment, requires a shorter duration of treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>], and is generally well tolerated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Moriarty et al, 2012</a>].<ul><li>A meta-analysis of five randomized controlled trials (RCTs) found that 4 weeks of terbinafine treatment was significantly more effective than 8 weeks of griseofulvin treatment in achieving complete (clinical and mycological) cure of confirmed <em>T. tonsurans</em> infection. The authors note that insufficient data were available to compare the two antifungal agents at equal treatment durations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Gupta and Drummond-Main, 2013</a>].</li><li>A further meta-analysis of a similar, more heterogeneous data set used different analytical parameters to compare drug efficacy, and came to the same conclusions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Tey et al, 2011</a>].</li><li>This is supported by a Cochrane systematic review of three RCTs (n = 328) of oral antifungal treatment in children, which found low-quality evidence that 4 weeks of terbinafine and 8 weeks of griseofulvin treatment showed similar efficacy for the primary outcome of complete cure in <em>Trichophyton</em> infections. A further RCT (n = 1006) provided moderate-quality evidence that terbinafine was more effective than griseofulvin in clearing infection. There was no significant difference in tolerability or adverse effects between the two agents [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Chen, 2016</a>].</li><li>The use of shorter treatment regimens with terbinafine potentially also improves compliance rates [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>].</li><li>The recommendation on the duration of terbinafine treatment is extrapolated from expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>].</li></ul></li></ul><h5>Prescribing oral griseofulvin treatment</h5><ul><li>The recommendation to prescribe griseofulvin first-line for <em>Microsporum</em> infections is based on the ESPD practice guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Kakourou et al, 2010</a>], two meta-analyses comparing griseofulvin and terbinafine treatments [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Tey et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Gupta and Drummond-Main, 2013</a>], a Cochrane systematic review [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Chen, 2016</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>]. It is a fungistatic drug which has traditionally been the gold standard treatment for fungal scalp infection in Europe with a long-term safety profile [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Kakourou et al, 2010</a>], and it is also the only drug licensed for the treatment of fungal scalp infection in children in the UK [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>].<ul><li>A meta-analysis of five RCTs found that 8 weeks of griseofulvin treatment was significantly more effective than 4 weeks of terbinafine treatment in achieving complete cure of confirmed <em>Microsporum</em> infection. The authors note that insufficient data were available to compare the two antifungal agents at equal treatment durations [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Gupta and Drummond-Main, 2013</a>].</li><li>A further meta-analysis of a similar, more heterogeneous data set used different analytical parameters to compare drug efficacy, and came to the same conclusions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Tey et al, 2011</a>].</li><li>In addition, a Cochrane systematic review of two studies (n = 334) of confirmed <em>Microsporum</em> scalp infection in children, found moderate-quality evidence that the complete cure rate with 6 weeks of terbinafine treatment was lower than with 6–12 weeks of griseofulvin treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Chen, 2016</a>].</li><li>The recommendation on the duration of griseofulvin treatment is based on the Medicines and Healthcare products Regulatory Agency's (MHRA) Summary of Product Characteristics (SPC) for griseofulvin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">MHRA, 2015</a>] and is extrapolated from expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>].</li></ul></li></ul><h5>Prescribing oral itraconazole treatment</h5><ul><li>The recommendation to consider itraconazole as an alternative to griseofulvin is based on expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>], a Cochrane systematic review of oral antifungal treatment in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Chen, 2016</a>], and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Moriarty et al, 2012</a>].<ul><li>Itraconazole has both fungicidal and fungistatic activity against dermatophytes, depending on the concentration of the drug in the tissues [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>].</li><li>It has the advantage of potentially shorter treatment courses than griseofulvin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>].</li><li>The Cochrane systematic review found very-low-quality evidence that complete cure rates were similar in two studies (n = 134) of children with confirmed fungal scalp infection which compared 2–6 weeks treatment with itraconazole to a 6-week course of griseofulvin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Chen, 2016</a>].</li><li>The recommendation on the duration of itraconazole treatment is extrapolated from expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>] and expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>].</li></ul></li></ul><h5>Prescribing topical antifungal adjuvant treatment</h5><ul><li>The recommendation to consider co-prescribing a topical antifungal as an adjunct at the start of oral antifungal treatment to prevent spread of infection, is extrapolated from expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>], the ESPD practice guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Kakourou et al, 2010</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Ely, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Hay, 2017</a>].<ul><li>The BAD guidelines recommend the use of selenium sulfide, ketoconazole, or povidone-iodine shampoos, and cite limited evidence from a small, randomized double-blind study (n = 40) which compared different antifungal shampoos as adjunctive treatments for fungal scalp infection in children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Chen, 2010</a>].<ul><li>It found that topical antifungal shampoos in addition to oral griseofulvin are sporicidal and can reduce the carriage and transmission of fungal spores to others, as well as physically removing adherent scale and spores from the scalp when applied. It noted, however, that the study had a small sample size and high rate of loss to follow-up.</li></ul></li><li>Expert opinion in the ESPD practice guidelines recommends the use of selenium sulfide or ketoconazole shampoo twice weekly for 2–4 weeks, or antifungal creams or lotions applied once daily for a week, which decrease the carriage of viable spores, and may shorten the oral antifungal time to cure [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Kakourou et al, 2010</a>]. Expert opinion in review articles also recommends this management approach [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Ely, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Hay, 2017</a>].</li></ul></li></ul><h5>Management of complications</h5><ul><li>The recommendation on the management of suspected secondary bacterial infection is pragmatic, based on what CKS considers to be good medical practice.</li><li>The recommendation on the management of a suspected id reaction is based on expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>] and in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>].</li></ul><h5>Assessing response to treatment</h5><ul><li>The recommendation on follow-up is extrapolated from the ESPD practice guidelines which recommend that oral antifungal treatment is stopped in children after repeat fungal culture is negative, or when there is clinical evidence of hair regrowth, to allow treatment to be tailored to each person depending on their individual response [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Kakourou et al, 2010</a>].</li></ul><!-- end field 301835f2-411e-4a2d-8669-f0bd2f9d50b2 --><!-- end item 935004a8-bd0e-4f9e-a0a8-fea5781911bb -->","subChapters":[]}]},{"id":"b2a3a4b6-5165-5a08-8b4b-07ee9cc97886","slug":"follow-up-referral","fullItemName":"Follow-up and referral","depth":3,"htmlHeader":"<!-- begin field befd2d45-315c-485d-8290-0890b3a24414 --><h3>When should I follow-up and refer?</h3><!-- end field befd2d45-315c-485d-8290-0890b3a24414 -->","summary":null,"htmlStringContent":"<!-- begin item 4cba064b-a1b0-4610-873d-c0697896cb37 --><!-- begin field 98917ff2-939f-44a3-bdb3-45748f79c858 --><p><strong>Review the person 4–8 weeks after completing first-line <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/management/management/#management-of-index-cases\">oral antifungal therapy</a> to assess the response to treatment.</strong></p><ul><li><strong>If normal hair regrowth does not occur and there are signs of persistent or recurrent infection:</strong><ul><li>Consider and, if possible, manage any underlying cause of treatment failure. This may include:<ul><li>Non-adherence to self-care advice or the treatment regimen.</li><li>Drug-resistant or multiple organisms.</li><li>Drug interactions or adverse effects.</li><li>Reinfection from close contacts or recurrence of infection.</li><li>An immuncompromised host.</li><li>An <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/diagnosis/differential-diagnosis/\">alternative diagnosis</a>.</li></ul></li><li>Arrange for repeat <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/diagnosis/assessment/#skin-hair-sampling\">skin and hair sampling</a> for fungal microscopy and culture.<ul><li>If there are signs of clinical improvement but ongoing positive mycology, consider continuing current oral antifungal treatment for a further 2–4 weeks and then reassess the person.</li><li>If repeat mycology is negative, no further oral antifungal treatment is needed.</li></ul></li></ul></li><li><strong>Arrange referral to a dermatology specialist, the urgency depending on clinical judgement, if:</strong><ul><li>The person has a suspected <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/diagnosis/diagnosis/\">kerion</a> — urgent referral should be arranged.</li><li>Oral antifungal treatment is being considered for a child, and there is insufficient experience and expertise to initiate this in primary care.</li><li>The diagnosis is uncertain.</li><li>Treatment in primary care is unsuccessful.</li><li>There is severe, extensive, or recurrent infection.</li><li>There is a suspected severe <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/background-information/complications/\">id reaction</a> which is not responding to treatment in primary care.</li><li>The person is immunocompromised, depending on clinical judgement.</li></ul></li></ul><!-- end field 98917ff2-939f-44a3-bdb3-45748f79c858 --><!-- end item 4cba064b-a1b0-4610-873d-c0697896cb37 -->","subChapters":[{"id":"3ebd4f91-72d9-50d5-9e6a-b29bd1c42fa6","slug":"basis-for-recommendation-39e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1cd716f3-276b-4797-abaa-6bf5d7eaa90e --><h4>Basis for recommendation</h4><!-- end field 1cd716f3-276b-4797-abaa-6bf5d7eaa90e -->","summary":null,"htmlStringContent":"<!-- begin item 39e6112e-eb5e-4121-b834-c52bd165ccb6 --><!-- begin field b4cff532-cc55-41cd-8cb8-f11900578c95 --><p>The recommendations on how to manage treatment failure and when to refer are largely based on expert opinion in the British Association of Dermatologists' (BAD) <em>Guidelines for the management of tinea capitis 2014</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>], and expert opinion in review articles on fungal scalp infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Hay, 2017</a>] and in review articles on fungal infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Ely, 2014</a>].</p><h5>Managing treatment failure</h5><ul><li>The recommendation on follow-up is extrapolated from the ESPD practice guidelines which recommend that oral antifungal treatment is stopped in children after repeat fungal culture is negative, or when there is clinical evidence of hair regrowth, to allow treatment to be tailored to each person depending on their individual response [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Kakourou et al, 2010</a>].</li><li>CKS notes that the BAD guidelines recommend post-treatment sampling for fungal microscopy and culture for <em>all</em> people with fungal scalp infection, to ensure clearance of infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>]. CKS has taken a more pragmatic approach to target people where there is suspected treatment failure, which is supported by expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Ely, 2014</a>] and the expert opinion of previous external reviewers of this CKS topic.</li><li>The recommendations on prescribing a prolonged course of first-line oral antifungal treatment if there are signs of clinical improvement but ongoing refractory infection are extrapolated from expert opinion in the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>]  and the Medicines and Healthcare products Regulatory Agency's (MHRA) Summary of Product Characteristics (SPC) for griseofulvin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">MHRA, 2015</a>]. Expert opinion in a review article also recommends this approach [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>].</li></ul><h5>Arranging referral to dermatology</h5><ul><li>The recommendation to arrange urgent referral for a suspected kerion is based on the fact that this needs a rapid diagnosis; may require high-dose oral antifungal treatment; may require specialist removal of thick superficial crust; and may need oral corticosteroid treatment in severe cases with widespread id reactions [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Moriarty et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Hay, 2017</a>]. In addition, expert opinion in a review article notes that children with kerion have a high false-negative culture rate, and if not treated promptly, it can lead to scarring and permanent hair loss [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Ely, 2014</a>].</li><li>Referral to a dermatologist may allow examination with a Wood's lamp, which may help to clarify the diagnosis and causative organism. <em>Microsporum</em> species demonstrate bright green fluorescence of infected hairs, whereas <em>Trichophyton</em> infection is generally non-fluorescent [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>].</li><li>The recommendation on referral of a suspected severe id reaction is extrapolated from the BAD guidelines, as this may occasionally need oral corticosteroid treatment to provide symptom relief [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>].</li></ul><!-- end field b4cff532-cc55-41cd-8cb8-f11900578c95 --><!-- end item 39e6112e-eb5e-4121-b834-c52bd165ccb6 -->","subChapters":[]}]},{"id":"a94857db-6b9c-5a47-b9fa-f8baceea43fc","slug":"management-of-contacts","fullItemName":"Management of contacts","depth":3,"htmlHeader":"<!-- begin field 8bc35a68-2487-4eef-8ad2-37f8cae533d0 --><h3>How should I manage contacts?</h3><!-- end field 8bc35a68-2487-4eef-8ad2-37f8cae533d0 -->","summary":null,"htmlStringContent":"<!-- begin item 149db174-650a-4b5d-a19a-837269bf8df0 --><!-- begin field ddbcd5f5-1d04-488d-bb04-e42be0ab7eb0 --><p><strong>If a person is a known <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/background-information/definition/\">contact</a> of a person with confirmed fungal scalp infection:</strong></p><ul><li>Arrange for <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/diagnosis/assessment/#skin-hair-sampling\">skin and hair sampling</a> for fungal culture, to determine if the contact has confirmed infection or is an asymptomatic carrier.<ul><li>If infection is confirmed and the person is symptomatic, offer <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/management/management/#management-of-index-cases\">self-care advice</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/management/management/#management-of-index-cases\">oral antifungal treatment</a>.</li><li>If the person is an asymptomatic <a class=\"topic-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/background-information/definition/\">carrier</a>, seek specialist advice from a dermatologist regarding ongoing management and follow-up.<ul><li>If there is a heavy growth or high spore count on brush culture, oral antifungal treatment may be needed.</li><li>If there is a low spore load, topical antifungal treatment with selenium sulfide or ketoconazole shampoo may be appropriate.</li></ul></li></ul></li></ul><!-- end field ddbcd5f5-1d04-488d-bb04-e42be0ab7eb0 --><!-- end item 149db174-650a-4b5d-a19a-837269bf8df0 -->","subChapters":[{"id":"689bf8b8-8c24-5eb6-b135-09bf8af102c0","slug":"basis-for-recommendation-0ad","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c9479019-9024-416e-a34a-5459ad5787b1 --><h4>Basis for recommendation</h4><!-- end field c9479019-9024-416e-a34a-5459ad5787b1 -->","summary":null,"htmlStringContent":"<!-- begin item 0ad7f442-c91d-4e79-be9c-4975ee2fd458 --><!-- begin field f02791b6-8752-4d15-b826-314451778cfe --><p>The recommendations on the management of contacts are largely based on expert opinion in the British Association of Dermatologists' (BAD) <em>Guidelines for the management of tinea capitis 2014</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>], the Public Health England (PHE) publication <em>Fungal skin and nail infections: Diagnosis and laboratory investigation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">PHE, 2017</a>], and expert opinion in review articles on fungal scalp infection [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Hay, 2017</a>].</p><ul><li>The recommendations on screening and treating positive contacts are based on expert opinion in the PHE publication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">PHE, 2017</a>] and in the BAD guidelines, which state that <em>Trichophyton</em> scalp infections are highly infectious and more than 50% of family members may be affected. If this is undetected and contacts are not treated, high recurrence rates are likely [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>].</li><li>The recommendations on the management of asymptomatic carriers is extrapolated from the BAD guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>] and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Hay, 2017</a>], as management options depend on the fungal spore load and underlying dermatophyte causative organism.<ul><li>It is important to fully treat asymptomatic carriers, as these people are responsible for fungal shedding and may be a reservoir for disease transmission and continued reinfection of index cases if they are untreated or partially treated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>].</li><li>Carriers with a high spore count may need oral antifungal treatment as they are more likely to develop an overt clinical fungal scalp infection, and are unlikely to respond to topical antifungal monotherapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Bennassar and Grimalt, 2010</a>].</li></ul></li></ul><!-- end field f02791b6-8752-4d15-b826-314451778cfe --><!-- end item 0ad7f442-c91d-4e79-be9c-4975ee2fd458 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}